Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Clinical trial NCT02168686 · COMPLETED

Trial details

NCT number: NCT02168686
Sponsor: Adverum Biotechnologies, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Alpha 1-Antitrypsin Deficiency

Start date: 2017-11-28
Primary completion: 2019-08-29
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.